Bronchopulmonary Dysplasia Treatment Market is expected to grow at a CAGR of 4.88% during the forecast period. The global Bronchopulmonary Dysplasia Treatment Market is expected to reach US$ 484.54 Mn. by 2029.Market Introduction and Overview
Bronchopulmonary dysplasia (BPD) is the most familiar chronic respiratory disease that results from complications related to the lung injury during the treatment of respiratory distress syndrome (RDS) in low-birth-weight premature infants, or when abnormal lung development occurs in older infants. New approaches in assisted ventilation, optimal nutrition, and pharmacologic interventions are boosting the market growth.To know about the Research Methodology :- Request Free Sample Report The key force driving the Bronchopulmonary dysplasia treatment market is the growth rate of infants who are at the high-risk of getting Bronchopulmonary dysplasia. According to research, every year, the number of infants getting affected by Bronchopulmonary dysplasia is increasing, which is propelling the demand for the treatment. Several other factors include increasing initiatives and efforts are taken by the government, favorable policies, the growing prominence of the disease, and increasing rate of premature births resulting in Bronchopulmonary dysplasia. Also, government initiatives, favorable reimbursement policies, the launch of novel drugs, strong pipeline, rising premature birth cases and an increase in health care expenditure are factors likely to fuel the global bronchopulmonary dysplasia treatment market during the forecast period. The report contains detailed analysis of Strengths, Weaknesses, and opportunities of the key players operating in Bronchopulmonary Dysplasia Market. It also provides information on current market trends, competitive ranking analysis, regional bifurcation, turnover forecasts, industry drivers and the key challenges. The report has profiled eight key players in the market from different regions. However, report has considered all market leaders, followers, and new entrants with investors while analysing the market and estimation the size of the same. The growing healthcare infrastructure in each region is different and focus is given on availability of advanced technology and new techniques.
Bronchopulmonary Dysplasia Market Segment Analysis
By drug type, the bronchodilators segment is expected to reach $xx Mn in the forecast period. The combination drug consisting of LABA and inhaled corticosteroid (ICS) is a therapeutic trend observed in the market. This therapy is gaining popularity owing to its effectiveness. It increases patient compliance, as it is administered as a once-daily dose. The market is set to witness the launch of many such therapies during the forecast period. These drugs suppress the immune response in individuals with asthma and reduce bronchial hyperactivity. There has been significant progress over the years in the management of airway disorders, bronchodilator treatment, which remains a key element in the therapy of these disorders, is still stuck in the use of β2-adrenoceptor agonists, muscarinic acetylcholine receptor (mAChR) antagonists and xanthines. In recent years, new targets for drugs to induce bronchodilation have been identified, which is fuelling the segment growth. Increase in prevalence of pulmonary disorders, growing technological advancements, and a rise in disposable income, increasing geriatric population and growing government initiatives for creating awareness among the general population are also the factors driving the segment. By therapy, the oxygen therapy segment accounted for a share of xx% in 2022 and is expected to reach $xx Mn in the forecast period. As per the National Institutes of Health (NIH), nearly 12 million adults have been diagnosed with COPD in the U.S. and 120,000 people die each year. The increasing patient population is expected to boost the demand for oxygen therapy. One of the mainstays of the treatment of BPD patients are the maintenance of appropriate arterial oxygen levels. In addition, the advent of the technologically advanced oxygen source and delivery devices, which offers efficient patient care, is expected to boost the segment.Regional Insights
North America accounted for the largest market share of xx% in 2022 and is expected to grow a CAGR of xx% in the forecast period. The high prevalence of the disease in the region and the rise in premature birth rate are factors fuelling the growth of the Bronchopulmonary dysplasia treatment market in the region. Growth in insurance coverage, presence of centers and institutes engaged in R&D and government funding are surging the North American market. Well-established healthcare infrastructure, ease of availability is also a key driver affecting the market growth. Investments by key players in this field have boosted the market growth. The rising adoption of technologically advanced diagnostic imaging systems for gene therapy is rapidly growing the market. Europe is also expected to drive the market and the factors responsible for growth are the growing acceptance of emerging technologies, rising incidence of chronic diseases is boosting the market growth. The Asia Pacific is also expected to witness significant growth during the forecast period due to rising health care expenditures. The allocation of a large amount of healthcare expenditure for hospitals and dispensing medicines to the elderly is expected to drive the market demand.Bronchopulmonary Dysplasia Market Scope: Inquire before Buying
Bronchopulmonary Dysplasia Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 347.12 Mn. Forecast Period 2023 to 2029 CAGR: 4.88% Market Size in 2029: US $ 484.54 Mn. Segments Covered: by Drug Type Bronchodilators Corticosteroids Diuretics Immunomodulators by Therapy Oxygen therapy Surfactant replacement therapy Mechanical ventilation Others by End user Hospitals Nursing homes Critical care unitsOthers Bronchopulmonary Dysplasia Market,By Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina and Rest of South America)Bronchopulmonary Dysplasia Market Key Players
1. Airway Therapeutics, LLC 2. Therabron Therapeutics 3. Syntrix Biosystems, Inc 4. CHIESI Farmaceutici S.p.A. 5. Meridigen Biotech 6. MediPost 7. Insmed 8. Martindale Pharmaceuticals Frequently Asked Questions: 1. Which region has the largest share in Global Bronchopulmonary Dysplasia Treatment Market? Ans: North America region held the highest share in 2022. 2. What is the growth rate of Global Bronchopulmonary Dysplasia Treatment Market? Ans: The Global Bronchopulmonary Dysplasia Treatment Market is growing at a CAGR of 4.88% during forecasting period 2023-2029. 3. What is scope of the Global Bronchopulmonary Dysplasia Treatment Market report? Ans: Global Bronchopulmonary Dysplasia Treatment Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. What was the Global Bronchopulmonary Dysplasia Treatment Market size in 2022? Ans: The Global Bronchopulmonary Dysplasia Treatment market was valued at US$ 347.12 Mn. In 2022. 5. What is the study period of this Market? Ans: The Global Bronchopulmonary Dysplasia Treatment Market is studied from 2022 to 2029.
Global Bronchopulmonary Dysplasia Treatment Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: BRONCHOPULMONARY DYSPLASIA TREATMENT Market Size, By Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global BRONCHOPULMONARY DYSPLASIA TREATMENT Market Analysis and Forecast 6.1. BRONCHOPULMONARY DYSPLASIA TREATMENT Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global BRONCHOPULMONARY DYSPLASIA TREATMENT Market Analysis and Forecast, By Drug Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. BRONCHOPULMONARY DYSPLASIA TREATMENT Market Value Share Analysis, By Drug Type 7.4. BRONCHOPULMONARY DYSPLASIA TREATMENT Market Size (US$ Mn) Forecast, By Drug Type 7.5. BRONCHOPULMONARY DYSPLASIA TREATMENT Market Analysis, By Drug Type 7.6. BRONCHOPULMONARY DYSPLASIA TREATMENT Market Attractiveness Analysis, By Drug Type 8. Global BRONCHOPULMONARY DYSPLASIA TREATMENT Market Analysis and Forecast, By Therapy 8.1. Introduction and Definition 8.2. Key Findings 8.3. BRONCHOPULMONARY DYSPLASIA TREATMENT Market Value Share Analysis, By Therapy 8.4. BRONCHOPULMONARY DYSPLASIA TREATMENT Market Size (US$ Mn) Forecast, By Therapy 8.5. BRONCHOPULMONARY DYSPLASIA TREATMENT Market Analysis, By Therapy 8.6. BRONCHOPULMONARY DYSPLASIA TREATMENT Market Attractiveness Analysis, By Therapy 9. Global BRONCHOPULMONARY DYSPLASIA TREATMENT Market Analysis and Forecast By End user 9.1. Introduction and Definition 9.2. Key Findings 9.3. BRONCHOPULMONARY DYSPLASIA TREATMENT Market Value Share Analysis, By End user 9.4. BRONCHOPULMONARY DYSPLASIA TREATMENT Market Size (US$ Mn) Forecast, By End user 9.5. BRONCHOPULMONARY DYSPLASIA TREATMENT Market Analysis, By End user 9.6. BRONCHOPULMONARY DYSPLASIA TREATMENT Market Attractiveness Analysis, By End user 10. Global BRONCHOPULMONARY DYSPLASIA TREATMENT Market Analysis, By Region 10.1. BRONCHOPULMONARY DYSPLASIA TREATMENT Market Value Share Analysis, By Region 10.2. BRONCHOPULMONARY DYSPLASIA TREATMENT Market Size (US$ Mn) Forecast, By Region 10.3. BRONCHOPULMONARY DYSPLASIA TREATMENT Market Attractiveness Analysis, By Region 11. North America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Analysis 11.1. Key Findings 11.2. North America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Overview 11.3. North America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Value Share Analysis, By Drug Type 11.4. North America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 11.4.1. Bronchodilators 11.4.2. Corticosteroids 11.4.3. Diuretics 11.4.4. Immunomodulators 11.5. North America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Value Share Analysis, By Therapy 11.6. North America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 11.6.1. Oxygen therapy 11.6.2. Surfactant replacement therapy 11.6.3. Mechanical ventilation 11.6.4. Others 11.7. North America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Value Share Analysis, By End user 11.8. North America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 11.8.1. Hospitals 11.8.2. Nursing homes 11.8.3. Critical care units 11.8.4. Others 11.9. North America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Value Share Analysis, By Country 11.10. North America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Country 11.10.1. U.S. 11.10.2. Canada 11.10.3. Mexico 11.11. North America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Analysis, By Country 11.12. U.S. BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 11.12.1. Bronchodilators 11.12.2. Corticosteroids 11.12.3. Diuretics 11.12.4. Immunomodulators 11.13. U.S. BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 11.13.1. Oxygen therapy 11.13.2. Surfactant replacement therapy 11.13.3. Mechanical ventilation 11.13.4. Others 11.14. U.S. BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 11.14.1. Hospitals 11.14.2. Nursing homes 11.14.3. Critical care units 11.14.4. Others 11.15. Canada BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 11.15.1. Bronchodilators 11.15.2. Corticosteroids 11.15.3. Diuretics 11.15.4. Immunomodulators 11.16. Canada BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 11.16.1. Oxygen therapy 11.16.2. Surfactant replacement therapy 11.16.3. Mechanical ventilation 11.16.4. Others 11.17. Canada BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 11.17.1. Hospitals 11.17.2. Nursing homes 11.17.3. Critical care units 11.17.4. Others 11.18. Mexico BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 11.18.1. Bronchodilators 11.18.2. Corticosteroids 11.18.3. Diuretics 11.18.4. Immunomodulators 11.19. Mexico BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 11.19.1. Oxygen therapy 11.19.2. Surfactant replacement therapy 11.19.3. Mechanical ventilation 11.19.4. Others 11.20. Mexico BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 11.20.1. Hospitals 11.20.2. Nursing homes 11.20.3. Critical care units 11.20.4. Others 11.21. North America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Attractiveness Analysis 11.21.1. By Drug Type 11.21.2. By Therapy 11.21.3. By End user 11.22. PEST Analysis 11.23. Key Trends 11.24. Key Developments 12. Europe BRONCHOPULMONARY DYSPLASIA TREATMENT Market Analysis 12.1. Key Findings 12.2. Europe BRONCHOPULMONARY DYSPLASIA TREATMENT Market Overview 12.3. Europe BRONCHOPULMONARY DYSPLASIA TREATMENT Market Value Share Analysis, By Drug Type 12.4. Europe BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 12.4.1. Bronchodilators 12.4.2. Corticosteroids 12.4.3. Diuretics 12.4.4. Immunomodulators 12.5. Europe BRONCHOPULMONARY DYSPLASIA TREATMENT Market Value Share Analysis, By Therapy 12.6. Europe BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 12.6.1. Oxygen therapy 12.6.2. Surfactant replacement therapy 12.6.3. Mechanical ventilation 12.6.4. Others 12.7. Europe BRONCHOPULMONARY DYSPLASIA TREATMENT Market Value Share Analysis, By End user 12.8. Europe BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 12.8.1. Hospitals 12.8.2. Nursing homes 12.8.3. Critical care units 12.8.4. Others 12.9. Europe BRONCHOPULMONARY DYSPLASIA TREATMENT Market Value Share Analysis, By Country 12.10. Europe BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Sweden 12.10.7. CIS countries 12.10.8. Rest of Europe 12.11. Germany BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 12.11.1. Bronchodilators 12.11.2. Corticosteroids 12.11.3. Diuretics 12.11.4. Immunomodulators 12.12. Germany BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 12.12.1. Oxygen therapy 12.12.2. Surfactant replacement therapy 12.12.3. Mechanical ventilation 12.12.4. Others 12.13. Germany BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 12.13.1. Hospitals 12.13.2. Nursing homes 12.13.3. Critical care units 12.13.4. Others 12.14. U.K. BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 12.14.1. Bronchodilators 12.14.2. Corticosteroids 12.14.3. Diuretics 12.14.4. Immunomodulators 12.15. U.K. BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 12.15.1. Oxygen therapy 12.15.2. Surfactant replacement therapy 12.15.3. Mechanical ventilation 12.15.4. Others 12.16. U.K. BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 12.16.1. Hospitals 12.16.2. Nursing homes 12.16.3. Critical care units 12.16.4. Others 12.17. France BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 12.17.1. Bronchodilators 12.17.2. Corticosteroids 12.17.3. Diuretics 12.17.4. Immunomodulators 12.18. France BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 12.18.1. Oxygen therapy 12.18.2. Surfactant replacement therapy 12.18.3. Mechanical ventilation 12.18.4. Others 12.19. France BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 12.19.1. Hospitals 12.19.2. Nursing homes 12.19.3. Critical care units 12.19.4. Others 12.20. Italy BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 12.20.1. Bronchodilators 12.20.2. Corticosteroids 12.20.3. Diuretics 12.20.4. Immunomodulators 12.21. Italy BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 12.21.1. Oxygen therapy 12.21.2. Surfactant replacement therapy 12.21.3. Mechanical ventilation 12.21.4. Others 12.22. Italy BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 12.22.1. Hospitals 12.22.2. Nursing homes 12.22.3. Critical care units 12.22.4. Others 12.23. Spain BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 12.23.1. Bronchodilators 12.23.2. Corticosteroids 12.23.3. Diuretics 12.23.4. Immunomodulators 12.24. Spain BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 12.24.1. Oxygen therapy 12.24.2. Surfactant replacement therapy 12.24.3. Mechanical ventilation 12.24.4. Others 12.25. Spain BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 12.25.1. Hospitals 12.25.2. Nursing homes 12.25.3. Critical care units 12.25.4. Others 12.26. Sweden BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 12.26.1. Bronchodilators 12.26.2. Corticosteroids 12.26.3. Diuretics 12.26.4. Immunomodulators 12.27. Sweden BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 12.27.1. Oxygen therapy 12.27.2. Surfactant replacement therapy 12.27.3. Mechanical ventilation 12.27.4. Others 12.28. Sweden BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 12.28.1. Hospitals 12.28.2. Nursing homes 12.28.3. Critical care units 12.28.4. Others 12.29. CIS countries BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 12.29.1. Bronchodilators 12.29.2. Corticosteroids 12.29.3. Diuretics 12.29.4. Immunomodulators 12.30. CIS countries BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 12.30.1. Oxygen therapy 12.30.2. Surfactant replacement therapy 12.30.3. Mechanical ventilation 12.30.4. Others 12.31. CIS countries BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 12.31.1. Hospitals 12.31.2. Nursing homes 12.31.3. Critical care units 12.31.4. Others 12.32. Rest of Europe BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 12.32.1. Bronchodilators 12.32.2. Corticosteroids 12.32.3. Diuretics 12.32.4. Immunomodulators 12.33. Rest of Europe BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 12.33.1. Oxygen therapy 12.33.2. Surfactant replacement therapy 12.33.3. Mechanical ventilation 12.33.4. Others 12.34. Rest of Europe BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 12.34.1. Hospitals 12.34.2. Nursing homes 12.34.3. Critical care units 12.34.4. Others 12.35. Europe BRONCHOPULMONARY DYSPLASIA TREATMENT Market Attractiveness Analysis 12.35.1. By Therapy 12.35.2. By Drug Type 12.35.3. By End user 12.36. PEST Analysis 12.37. Key Trends 12.38. Key Developments 13. Asia Pacific BRONCHOPULMONARY DYSPLASIA TREATMENT Market Analysis 13.1. Key Findings 13.2. Asia Pacific BRONCHOPULMONARY DYSPLASIA TREATMENT Market Overview 13.3. Asia Pacific BRONCHOPULMONARY DYSPLASIA TREATMENT Market Value Share Analysis, By Drug Type 13.4. Asia Pacific BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 13.4.1. Bronchodilators 13.4.2. Corticosteroids 13.4.3. Diuretics 13.4.4. Immunomodulators 13.5. Asia Pacific BRONCHOPULMONARY DYSPLASIA TREATMENT Market Value Share Analysis, By Therapy 13.6. Asia Pacific BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 13.6.1. Oxygen therapy 13.6.2. Surfactant replacement therapy 13.6.3. Mechanical ventilation 13.6.4. Others 13.7. Asia Pacific BRONCHOPULMONARY DYSPLASIA TREATMENT Market Value Share Analysis, By End user 13.8. Asia Pacific BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 13.8.1. Hospitals 13.8.2. Nursing homes 13.8.3. Critical care units 13.8.4. Others 13.9. Asia Pacific BRONCHOPULMONARY DYSPLASIA TREATMENT Market Value Share Analysis, By Country 13.10. Asia Pacific BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. South Korea 13.10.5. Australia 13.10.6. ASEAN 13.10.7. Rest of Asia Pacific 13.11. Asia Pacific BRONCHOPULMONARY DYSPLASIA TREATMENT Market Analysis, By Country 13.12. China BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 13.12.1. Bronchodilators 13.12.2. Corticosteroids 13.12.3. Diuretics 13.12.4. Immunomodulators 13.13. China BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 13.13.1. Oxygen therapy 13.13.2. Surfactant replacement therapy 13.13.3. Mechanical ventilation 13.13.4. Others 13.14. China BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 13.14.1. Hospitals 13.14.2. Nursing homes 13.14.3. Critical care units 13.14.4. Others 13.15. India BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 13.15.1. Bronchodilators 13.15.2. Corticosteroids 13.15.3. Diuretics 13.15.4. Immunomodulators 13.16. India BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 13.16.1. Oxygen therapy 13.16.2. Surfactant replacement therapy 13.16.3. Mechanical ventilation 13.16.4. Others 13.17. India BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 13.17.1. Hospitals 13.17.2. Nursing homes 13.17.3. Critical care units 13.17.4. Others 13.18. Japan BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 13.18.1. Bronchodilators 13.18.2. Corticosteroids 13.18.3. Diuretics 13.18.4. Immunomodulators 13.19. Japan BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 13.19.1. Oxygen therapy 13.19.2. Surfactant replacement therapy 13.19.3. Mechanical ventilation 13.19.4. Others 13.20. Japan BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 13.20.1. Hospitals 13.20.2. Nursing homes 13.20.3. Critical care units 13.20.4. Others 13.21. South Korea BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 13.21.1. Bronchodilators 13.21.2. Corticosteroids 13.21.3. Diuretics 13.21.4. Immunomodulators 13.22. South Korea BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 13.22.1. Oxygen therapy 13.22.2. Surfactant replacement therapy 13.22.3. Mechanical ventilation 13.22.4. Others 13.23. South Korea BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 13.23.1. Hospitals 13.23.2. Nursing homes 13.23.3. Critical care units 13.23.4. Others 13.24. Australia BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 13.24.1. Bronchodilators 13.24.2. Corticosteroids 13.24.3. Diuretics 13.24.4. Immunomodulators 13.25. Australia BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 13.25.1. Oxygen therapy 13.25.2. Surfactant replacement therapy 13.25.3. Mechanical ventilation 13.25.4. Others 13.26. Australia BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 13.26.1. Hospitals 13.26.2. Nursing homes 13.26.3. Critical care units 13.26.4. Others 13.27. ASEAN BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 13.27.1. Bronchodilators 13.27.2. Corticosteroids 13.27.3. Diuretics 13.27.4. Immunomodulators 13.28. ASEAN BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 13.28.1. Oxygen therapy 13.28.2. Surfactant replacement therapy 13.28.3. Mechanical ventilation 13.28.4. Others 13.29. ASEAN BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 13.29.1. Hospitals 13.29.2. Nursing homes 13.29.3. Critical care units 13.29.4. Others 13.30. Rest of Asia Pacific BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 13.30.1. Bronchodilators 13.30.2. Corticosteroids 13.30.3. Diuretics 13.30.4. Immunomodulators 13.31. Rest of Asia Pacific BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 13.31.1. Oxygen therapy 13.31.2. Surfactant replacement therapy 13.31.3. Mechanical ventilation 13.31.4. Others 13.32. Rest of Asia Pacific BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 13.32.1. Hospitals 13.32.2. Nursing homes 13.32.3. Critical care units 13.32.4. Others 13.33. Asia Pacific BRONCHOPULMONARY DYSPLASIA TREATMENT Market Attractiveness Analysis 13.33.1. By Drug Type 13.33.2. By Therapy 13.33.3. By End user 13.34. PEST Analysis 13.35. Key Trends 13.36. Key Developments 14. Middle East & Africa BRONCHOPULMONARY DYSPLASIA TREATMENT Market Analysis 14.1. Key Findings 14.2. Middle East & Africa BRONCHOPULMONARY DYSPLASIA TREATMENT Market Overview 14.3. Middle East & Africa BRONCHOPULMONARY DYSPLASIA TREATMENT Market Value Share Analysis, By Drug Type 14.4. Middle East & Africa BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 14.4.1. Bronchodilators 14.4.2. Corticosteroids 14.4.3. Diuretics 14.4.4. Immunomodulators 14.5. Middle East & Africa BRONCHOPULMONARY DYSPLASIA TREATMENT Market Value Share Analysis, By Therapy 14.6. Middle East & Africa BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 14.6.1. Oxygen therapy 14.6.2. Surfactant replacement therapy 14.6.3. Mechanical ventilation 14.6.4. Others 14.7. Middle East & Africa BRONCHOPULMONARY DYSPLASIA TREATMENT Market Value Share Analysis, By End user 14.8. Middle East & Africa BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 14.8.1. Hospitals 14.8.2. Nursing homes 14.8.3. Critical care units 14.8.4. Others 14.9. Middle East & Africa BRONCHOPULMONARY DYSPLASIA TREATMENT Market Value Share Analysis, By Country 14.10. Middle East & Africa BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Country 14.10.1. GCC Countries 14.10.2. South Africa 14.10.3. Nigeria 14.10.4. Egypt 14.10.5. Rest of Middle East & Africa 14.11. Middle East & Africa BRONCHOPULMONARY DYSPLASIA TREATMENT Market Analysis, By Country 14.12. GCC Countries BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 14.12.1. Bronchodilators 14.12.2. Corticosteroids 14.12.3. Diuretics 14.12.4. Immunomodulators 14.13. GCC Countries BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 14.13.1. Oxygen therapy 14.13.2. Surfactant replacement therapy 14.13.3. Mechanical ventilation 14.13.4. Others 14.14. GCC Countries BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 14.14.1. Hospitals 14.14.2. Nursing homes 14.14.3. Critical care units 14.14.4. Others 14.15. South Africa BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 14.15.1. Bronchodilators 14.15.2. Corticosteroids 14.15.3. Diuretics 14.15.4. Immunomodulators 14.16. South Africa BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 14.16.1. Oxygen therapy 14.16.2. Surfactant replacement therapy 14.16.3. Mechanical ventilation 14.16.4. Others 14.17. South Africa BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 14.17.1. Hospitals 14.17.2. Nursing homes 14.17.3. Critical care units 14.17.4. Others 14.18. Nigeria BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 14.18.1. Bronchodilators 14.18.2. Corticosteroids 14.18.3. Diuretics 14.18.4. Immunomodulators 14.19. Nigeria BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 14.19.1. Oxygen therapy 14.19.2. Surfactant replacement therapy 14.19.3. Mechanical ventilation 14.19.4. Others 14.20. Nigeria BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 14.20.1. Hospitals 14.20.2. Nursing homes 14.20.3. Critical care units 14.20.4. Others 14.21. Egypt BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 14.21.1. Bronchodilators 14.21.2. Corticosteroids 14.21.3. Diuretics 14.21.4. Immunomodulators 14.22. Egypt BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 14.22.1. Oxygen therapy 14.22.2. Surfactant replacement therapy 14.22.3. Mechanical ventilation 14.22.4. Others 14.23. Egypt BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 14.23.1. Hospitals 14.23.2. Nursing homes 14.23.3. Critical care units 14.23.4. Others 14.24. Rest of Middle East & Africa BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 14.24.1. Bronchodilators 14.24.2. Corticosteroids 14.24.3. Diuretics 14.24.4. Immunomodulators 14.25. Rest of Middle East & Africa BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 14.25.1. Oxygen therapy 14.25.2. Surfactant replacement therapy 14.25.3. Mechanical ventilation 14.25.4. Others 14.26. Rest of Middle East & Africa BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 14.26.1. Hospitals 14.26.2. Nursing homes 14.26.3. Critical care units 14.26.4. Others 14.27. Middle East & Africa BRONCHOPULMONARY DYSPLASIA TREATMENT Market Attractiveness Analysis 14.27.1. By Drug Type 14.27.2. By Therapy 14.27.3. By End user 14.28. PEST Analysis 14.29. Key Trends 14.30. Key Developments 15. South America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Analysis 15.1. Key Findings 15.2. South America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Overview 15.3. South America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Value Share Analysis, By Drug Type 15.4. South America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 15.4.1. Bronchodilators 15.4.2. Corticosteroids 15.4.3. Diuretics 15.4.4. Immunomodulators 15.5. South America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Value Share Analysis, By Therapy 15.6. South America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 15.6.1. Oxygen therapy 15.6.2. Surfactant replacement therapy 15.6.3. Mechanical ventilation 15.6.4. Others 15.7. South America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Value Share Analysis, By End user 15.8. South America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 15.8.1. Hospitals 15.8.2. Nursing homes 15.8.3. Critical care units 15.8.4. Others 15.9. South America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Value Share Analysis, By Country 15.10. South America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Country 15.10.1. Brazil 15.10.2. Colombia 15.10.3. Argentina 15.10.4. Rest of South America 15.11. South America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Analysis, By Country 15.12. Brazil BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 15.12.1. Bronchodilators 15.12.2. Corticosteroids 15.12.3. Diuretics 15.12.4. Immunomodulators 15.13. Brazil BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 15.13.1. Oxygen therapy 15.13.2. Surfactant replacement therapy 15.13.3. Mechanical ventilation 15.13.4. Others 15.14. Brazil BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 15.14.1. Hospitals 15.14.2. Nursing homes 15.14.3. Critical care units 15.14.4. Others 15.15. Colombia BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 15.15.1. Bronchodilators 15.15.2. Corticosteroids 15.15.3. Diuretics 15.15.4. Immunomodulators 15.16. Colombia BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 15.16.1. Oxygen therapy 15.16.2. Surfactant replacement therapy 15.16.3. Mechanical ventilation 15.16.4. Others 15.17. Colombia BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 15.17.1. Hospitals 15.17.2. Nursing homes 15.17.3. Critical care units 15.17.4. Others 15.18. Argentina BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 15.18.1. Bronchodilators 15.18.2. Corticosteroids 15.18.3. Diuretics 15.18.4. Immunomodulators 15.19. Argentina BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 15.19.1. Oxygen therapy 15.19.2. Surfactant replacement therapy 15.19.3. Mechanical ventilation 15.19.4. Others 15.20. Argentina BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 15.20.1. Hospitals 15.20.2. Nursing homes 15.20.3. Critical care units 15.20.4. Others 15.21. Rest of South America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Drug Type 15.21.1. Bronchodilators 15.21.2. Corticosteroids 15.21.3. Diuretics 15.21.4. Immunomodulators 15.22. Rest of South America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By Therapy 15.22.1. Oxygen therapy 15.22.2. Surfactant replacement therapy 15.22.3. Mechanical ventilation 15.22.4. Others 15.23. Rest of South America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Forecast, By End user 15.23.1. Hospitals 15.23.2. Nursing homes 15.23.3. Critical care units 15.23.4. Others 15.24. South America BRONCHOPULMONARY DYSPLASIA TREATMENT Market Attractiveness Analysis 15.24.1. By Drug Type 15.24.2. By Therapy 15.24.3. By End user 15.25. PEST Analysis 15.26. Key Trends 15.27. Key Developments 16. Company Profiles 16.1. Market Share Analysis, By Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players By price, presence, market share, Therapy, and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A By Regions, Investment and Therapy 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Airway Therapeutics, LLC 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Therabron Therapeutics 16.3.3. Syntrix Biosystems, Inc 16.3.4. CHIESI Farmaceutici S.p.A. 16.3.5. Meridigen Biotech 16.3.6. MediPost 16.3.7. Insmed 16.3.8. Martindale Pharmaceuticals 16.3.9. Others